Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist

被引：1

作者：

Shenoy, Niraj ^{[1
]}

Pagliaro, Lance ^{[1
]}

机构：

[1] Mayo Clin, Dept Med Oncol, 200 First St SW, Rochester, MN 55905 USA

来源：

EUROPEAN UROLOGY | 2018年 / 73卷 / 02期

关键词：

HIF1-ALPHA;

D O I：

10.1016/j.eururo.2017.10.007

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：304 / 305

页数：4

共 50 条

[21] Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Ricketts, Christopher J.
Crooks, Daniel R.
Linehan, W. Marston
CANCER CELL, 2016, 30 (04) : 515 - 517
[22] Targeting the HIF2-VEGF axis in renal cell carcinoma
Choueiri, Toni K.
Kaelin, William G., Jr.
NATURE MEDICINE, 2020, 26 (10) : 1519 - 1530
[23] HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice
Rouven Hoefflin
Sabine Harlander
Silvia Schäfer
Patrick Metzger
Fengshen Kuo
Désirée Schönenberger
Mojca Adlesic
Asin Peighambari
Philipp Seidel
Chia-yi Chen
Miguel Consenza-Contreras
Andreas Jud
Bernd Lahrmann
Niels Grabe
Danijela Heide
Franziska M. Uhl
Timothy A. Chan
Justus Duyster
Robert Zeiser
Christoph Schell
Mathias Heikenwalder
Oliver Schilling
A. Ari Hakimi
Melanie Boerries
Ian J. Frew
Nature Communications, 11
[24] HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma
Bacigalupa, Zachary A.
Arner, Emily N.
Vlach, Logan M.
Wolf, Melissa M.
Brown, Whitney A.
Krystofiak, Evan S.
Ye, Xiang
Hongo, Rachel A.
Landis, Madelyn
Amason, Edith K.
Beckermann, Kathryn E.
Rathmell, W. Kimryn
Rathmell, Jeffrey C.
JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (12):
[25] HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice
Hoefflin, Rouven
Harlander, Sabine
Schaefer, Silvia
Metzger, Patrick
Kuo, Fengshen
Schoenenberger, Desiree
Adlesic, Mojca
Peighambari, Asin
Seidel, Philipp
Chen, Chia-yi
Consenza-Contreras, Miguel
Jud, Andreas
Lahrmann, Bernd
Grabe, Niels
Heide, Danijela
Uhl, Franziska M.
Chan, Timothy A.
Duyster, Justus
Zeiser, Robert
Schell, Christoph
Heikenwalder, Mathias
Schilling, Oliver
Hakimi, A. Ari
Boerries, Melanie
Frew, Ian J.
NATURE COMMUNICATIONS, 2020, 11 (01)
[26] First HIF-2 antagonist for VHL tumors
Nature Biotechnology, 2021, 39 (9) : 1032 - 1032
[27] Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy
Davis, Leah
Recktenwald, Matthias
Hutt, Evan
Fuller, Schuyler
Briggs, Madison
Goel, Arnav
Daringer, Nichole
CANCERS, 2022, 14 (05)
[28] Prognostic value of CD147 and HIF-2α expression in localized clear cell renal cell carcinoma
Li, Hao
Zhang, Tian
Zhang, Yang
Wang, Pei
Bian, Huijie
Chen, Zhi-Nan
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (09): : 9394 - 9400
[29] Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers?
Nogueira, Ines
Dias, Francisca
Morais, Mariana
Teixeira, Ana Luisa
Medeiros, Rui
FUTURE ONCOLOGY, 2019, 15 (20) : 2361 - 2370
[30] HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Courtney, Kevin D.
Ma, Yuanqing
de Leon, Alberto Diaz
Christie, Alana
Xie, Zhiqun
Woolford, Layton
Singla, Nirmish
Joyce, Allison
Hill, Haley
Madhuranthakam, Ananth J.
Yuan, Qing
Xi, Yin
Zhang, Yue
Chang, Jenny
Fatunde, Oluwatomilade
Arriaga, Yull
Frankel, Arthur E.
Kalva, Sanjeeva
Zhang, Song
McKenzie, Tiffani
Torras, Oscar Reig
Figlin, Robert A.
Rini, Brian, I
McKay, Renee M.
Kapur, Payal
Wang, Tao
Pedrosa, Ivan
Brugarolas, James
CLINICAL CANCER RESEARCH, 2020, 26 (04) : 793 - 803

← 1 2 3 4 5 →